A Study of AL102 in Patients With Progressing Desmoid Tumors
Trial details
- Registry ID
- NCT04871282
- Drugs studied
- AL102
TrialRedline tracks 1 clinical trial sponsored by Immunome, Inc.: 1 Phase 2 / 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282 | AL102 | Active not recruiting | 2025-12-03Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptan NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptVaregacestat PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |
Names as written in the registry records.
NCT04871282 · Immunome, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression free survival. After: Measure: Part A: Safety and Tolerability - Adverse Events Measure: Part B: Progression free survival (PFS).
NCT04871282 · Immunome, Inc.
Before: Estimated. After: Actual.
Before: Oct 2025. After: 3 Dec 2025.